Wockhardt Ltd has signed an In-licensing agreement with UK-based LSI to market Vitix, a drug used for treating pigmentation disorder.
Vitix is a gel for topical application and would be manufactured by the company in India from active pharmaceutical ingredients imported from LSI, Wockhardt informed the Bombay Stock Exchange.
The drug offers advantages like fast onset of action and high success rate with established safety. Vitix is now marketed in Europe, North America, South East Asia and Africa.
"This agreement is part of the Wockhardt's initiative to bring new advances in medicine to India," Wockhardt chairman Habil Khorakiwala said.
Vitix, a patented product for the treatment of vitiligo, is expected to be launched in India in the last quarter of this year.
Vitiligo, also known as leucoderma, is a skin disorder affecting 1 per cent to 2 per cent of the global population in which the patient develops white patches caused by localised loss of pigment.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
